Post marketing safety assessment of the novel postpartum depression drug, Zuranolone: evidence from real-world pharmacovigilance analysis based on the FDA adverse event reporting system.

The remaining systems did not show a clear trend due to limited data. 3.4 Comparative reporting risk with other drugs against perinatal depression Zuranolone, as an enhanced version of Brexanolone, which was marketed in 2019 for intravenous administration in adult patients with PPD and has the same mechanism of action, was compared to Brexanolone to analyze the association of adverse reactions between Zuranolone and Brexanolone ( 18 ).

also in 19,460 other papers